Evidence map›Paper›PMID 38003307›Full record

ArticleInternational journal of molecular sciences2023

First Report of

Manel Gharbi, Mohammed Abdo Saghir Abbas, Safa Hamrouni, Abderrazak Maaroufi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Applied and environmental microbiology · 2026
    Article
  2. Article
  3. Heteroresistance to amikacin inMicrobiology spectrum · 2026
    Article
  4. Fluoroquinolone Resistance Patterns in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  5. Identification of the Phenicol Efflux GeneInternational journal of microbiology · 2026
    Article
  6. Article
  7. Resistance Mechanisms of Fluoroquinolone inAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Mutational Analysis of Colistin-ResistantPathogens (Basel, Switzerland) · 2025
    Article
  9. The Global Challenge ofTropical medicine and infectious disease · 2025
    Review
  10. Review
  11. Occurrence of Florfenicol and Linezolid Resistance and Emergence ofInternational journal of microbiology · 2024
    Article
  12. Defense mechanisms ofFrontiers in antibiotics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Manel GharbiGroup of Bacteriology and Biotechnology Development, Laboratory of Epidemiology and Veterinary Microbiology, Institut Pasteur de Tunis, University of Tunis El Manar (UTM), Tunis 1002, Tunisia.
Mohammed Abdo Saghir AbbasUnit of Vector Ecology, Pasteur Institute of Tunis, Tunis 1002, Tunisia.ORCID 0000-0002-9428-2461
Safa HamrouniGroup of Bacteriology and Biotechnology Development, Laboratory of Epidemiology and Veterinary Microbiology, Institut Pasteur de Tunis, University of Tunis El Manar (UTM), Tunis 1002, Tunisia.
Abderrazak MaaroufiGroup of Bacteriology and Biotechnology Development, Laboratory of Epidemiology and Veterinary Microbiology, Institut Pasteur de Tunis, University of Tunis El Manar (UTM), Tunis 1002, Tunisia.
Tunis University · TNInstitut Pasteur de Tunis · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The

Indexed as

Campylobacter coliFluoroquinolonesAminoglycosidesAnimalsAnti-Bacterial AgentsChickensDrug Resistance, BacterialEscherichia coliFemaleMicrobial Sensitivity TestsMutationTunisiaAminoglycosidesAnti-Bacterial AgentsFluoroquinolonesaac(6′)-Ib-crCampylobacterfluoroquinolone-resistancephylogenypoultry

Identifiers

PMID38003307
PMCPMC10671610
OpenAlexW4388534498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.